| Literature DB >> 12943493 |
Anne R Miller1, Garret J Etgen.
Abstract
As the incidence of Type 2 diabetes has reached near epidemic proportions, the quest for novel therapies to combat this disorder has intensified dramatically. In recent years, the peroxisome proliferator-activated receptor (PPAR) family has received tremendous attention as perhaps an ideal target class to address the multiple metabolic anomalies associated with the diabetic state. This review focuses on a variety of novel PPAR approaches currently being investigated for Type 2 diabetes or the metabolic syndrome, including the highly potent selective PPAR agonists, PPAR combination agonists and alternative PPAR ligands.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12943493 DOI： 10.1517/13543784.12.9.1489
Source DB: PubMed Journal: Expert Opin Investig Drugs ISSN： 1354-3784 Impact factor: 6.206